Fig. 4
In vivo antitumor effects of Ad-ΔB and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 on an orthotopic transplanted mouse model of human HCC. The model was induced by intrahepatic implantation of 2 × 106 human Hep3B/fluc cells into the left liver lobes of mice in athymic nude mice. Positive HCC-bearing mice were thereafter randomized into three groups (n = 10/group) and through their tail veins they were treated with: PBS alone (Group 1), Ad-ΔB (Group 2), and Ad-ΔB/TRAIL+Ad-ΔB/IL-12 (Group 3) at a dosage regimen of 1 × 1010 VP in 200 μL PBS of each virus; repeated three times every other day. Next, the mice were monitored and photographed (a) weekly by in vivo bioluminescence imaging to determine the pattern of tumor response to the subjected treatments (b) until the end of study (day 14 post-the last treatment dose)